Clinical trials: Histological Type of Neoplasm
Renal Cancer, Renal Neoplasm
Laparoscopic Partial Nephrectomy for cT1 Tumors
The aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (LNP) in patients with clinical T1N0M0 renal tumor.
- Conditions
- Renal Cancer, Renal Neoplasm, Renal Cell Carcinoma, Surgery
- Trial name
- NCT04213157
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 292 people
- Sponsor
- Samsun Liv Hospital
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Malignant Liver Tumor
Deportalization, Venous Deprivation, Venous Congestion
Patients with multiple primary or secondary liver tumors have a low survival rate unless they can benefit from curative extended hepatic resections with R0 or R1 marge resection.
- Trial name
- NCT03995459
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Montpellier
Acoustic Schwannoma, Adult Anaplastic Meningioma
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma
- Trial name
- NCT01125046
- Testing
- bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Metastatic Hepatocellular Carcinoma
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
To learn about the safety and tolerability of atezolizumab, bevacizumab, and ADI-PEG 20 when given in combination to patients with locally advanced or metastatic liver cancer
- Trial name
- NCT06006286
- Testing
- Atezolizumab, Bevacizumab, ADI-PEG 20
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Cancer Survivor, Stage IA Ovarian Epithelial Cancer
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
This pilot clinical trial studies survivorship care planning in supporting quality of life in ovarian cancer survivors following primary treatment.
- Conditions
- Cancer Survivor, Stage IA Ovarian Epithelial Cancer, Stage IB Ovarian Epithelial Cancer, Stage IC Ovarian Epithelial Cancer
- Trial name
- NCT02082470
- Testing
- follow-up care, active surveillance, questionnaire administration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Chronic Myelomonocytic Leukemia (CMML)
Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
This is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic…
- Trial name
- NCT07588594
- Testing
- TBF regimen
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Peking University People's Hospital
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma.
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
- Trial name
- NCT05602194
- Testing
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine
- Where
- 228 sites in United States, Canada
- Volunteers
- 440 people
- Sponsor
- Children's Oncology Group
Basal Cell Carcinoma
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
To assess the efficacy of treating a nodular basal cell carcinoma with imiquimod cream after initial treatment with curettage
- Trial name
- NCT00314756
- Testing
- imiquimod
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Multiple Myeloma
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- NCT06892522
- Testing
- Etentamig, Lenalidomide, Dexamethasone
- Where
- 36 sites in United States, Australia and 4 more
- Volunteers
- 602 people
- Sponsor
- AbbVie
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00182702
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Carcinoma
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma.
- Trial name
- NEOPAN (NCT02539537)
- Testing
- Gemcitabine, Folinic Acid, 5-Fluoro-uracil
- Where
- 45 sites in France
- Volunteers
- 171 people
- Sponsor
- UNICANCER
AML (Acute Myelogenous Leukemia, HSCT
Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.
The goal of this clinical trial is to treat adult patients with relapsed/refractory acute myeloid leukemia (AML) using a salvage chemotherapy regimen consisting of Sonrotoclax, cladribine, and standard-dose cytarabine…
- Trial name
- NCT07757672
- Testing
- Sonrotoclax, cladribine, and standard-dose cytarabine
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Renal Cell Carcinoma, Kidney Cancer
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Advanced renal cell carcinoma is invariably fatal, with a life expectancy of 2-3 years since diagnosis. Sunitinib is the standard first-line treatment for this condition, but it is associated to multiple side effects, with…
- Trial name
- QUASAR (NCT02446795)
- Testing
- Sunitinib, Isoquercetin
- Where
- 5 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Consorzio Oncotech
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01107639
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 57 sites in Austria, France and 3 more
- Volunteers
- 297 people
- Sponsor
- Swiss Cancer Institute
Endocrine and Neuroendocrine Tumors
SPECT/CT in Endocrine and Neuroendocrine Tumors
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT).
- Trial name
- NCT00230139
- Testing
- SPECT/CT
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04850495
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Yazeed Sawalha
Thymic Carcinoma
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.
- Trial name
- NCT01011439
- Testing
- Milciclib Maleate
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- Tiziana Life Sciences LTD
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma
Safety and efficacy of doxorubicin-eluting-bead embolization in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT02525380
- Testing
- Device(DC Bead)
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Peripheral T-cell Lymphoma
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
There is no data comparing the effectiveness of the 4 most relevant first-line therapy programs for peripheral T-cell lymphomas (CHOEP, CHOP, CHEP-BV, CHP-BV) in a single study.
- Trial name
- BrEto-TCL (NCT07258680)
- Testing
- Doxorubicin, Vincristine, Etoposide
- Volunteers
- 114 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.